Clinical Effectiveness and Nephrotoxicity of Aerosolized Colistin Treatment in Multidrug-Resistant Gram-Negative Pneumonia

다국어 초록 (Multilingual Abstract)

Background: Colistin (polymyxin E) is active against multidrug-resistant Gram-negative bacteria (MDR-GNB). However, the effectiveness of inhaled colistin is unclear. This study was designed to assess the effectiveness and safety of aerosolized colistin for the treatment of ventilator-associated pneumonia (VAP) caused by MDR-GNB.
Methods: In this retrospective longitudinal study, we evaluated the medical records of 63 patients who received aerosolized colistin treatment for VAP caused by MDR-GNB in the medical intensive care unit (MICU) from February 2012 to March 2014.
Results: A total of 25 patients with VAP caused by MDR-GNB were included in this study. The negative conversion rate was 84.6% after treatment, and acute kidney injury (AKI) occurred in 11 patients (44%, AKI group). The average length of MICU stay and colistin treatment- related factors, such as daily and total cumulative doses and administration period, were not significantly different between groups. In-hospital mortality tended to be higher in the AKI group (p = 0.07). Multivariate analysis showed that a body mass index less than 18 was an independent risk factor of mortality (odds ratio [OR] = 21.95, 95% confidence interval [CI] 1.59-302.23; p = 0.02). Notably, AKI occurrence was closely related to the administration of more than two nephrotoxic drugs combined with aerosolized colistin (OR = 15.03, 95% CI 1.40-161.76; p = 0.025) and septic shock (OR = 8.10, 95% CI 1.40-161.76; p = 0.04).
Conclusions: The use of adjunctive aerosolized colistin treatment appears to be a relatively safe and effective option for the treatment of VAP caused by MDR-GNB. However, more research on the concomitant use of nephrotoxic drugs with aerosolized colistin will be necessary, as this can be an important risk factor of development of AKI.

참고문헌 (Reference)

1 Kollef MH, "Why is Acinetobacter baumannii a problem for critically ill patients?" 41 : 2170-2172, 2015

2 Sorlí L, "Trough colistin plasma level is an independent risk factor for nephrotoxicity: a prospective observational cohort study" 13 : 380-388, 2013

3 Hamer DH, "Treatment of nosocomial pneumonia and tracheobronchitis caused by multidrug-resistant Pseudomonas aeruginosa with aerosolized colistin" 162 : 328-330, 2000

4 Falagas ME, "Toxicity of polymyxins:a systematic review of the evidence from old and recent studies" 10 : R27-, 2006

5 Hogue CW Jr, "The impact of obesity on outcomes after critical illness: a meta-analysis" 35 : 1152-1170, 2009

6 Arabi YM, "The Cooperative Antimicrobial Therapy of Septic Shock (CATSS) Database Research Group. Clinical characteristics, sepsis interventions and outcomes in the obese patients with septic shock: an international multicenter cohort study" 17 : R72-, 2013

7 Imberti R, "Steady-state pharmacokinetics and BAL concentration of colistin in critically Ill patients after IV colistin methanesulfonate administration" 138 : 1333-1339, 2010

8 Yapa SWS, "Pulmonary and systemic pharmacokinetics of inhaled and intravenous colistin methanesulfonate in cystic fibrosis patients: targeting advantage of inhalational administration" 58 : 2570-2579, 2014

9 Kaye KS, "Principles and practice of infectious diseases" Elsevier 435-436, 2005

10 Evans ME, "Polymyxin B sulfate and colistin: old antibi-otics for emerging multiresistant gram-negative bacteria" 33 : 960-967, 1999

11 Marchand S, "Pharmacokinetics of Colistin Methansulphonate (CMS) and Colistin after CMS Nebulisation in Baboon Monkeys" 32 : 3404-3414, 2015

12 Hancock RE, "Peptide antibiotics" 349 : 418-422, 1997

13 Hartzell JD, "Nephrotoxicity associated with intravenous colistin (colistimethate sodium) treatment at a tertiary care medical center" 48 : 1724-1728, 2009

14 Korbila IP, "Inhaled colistin as adjunctive to intravenous colistin for the treatment of microbiologically documented VAP: a comparative cohort study" 16 : 1230-1236, 2010

15 Bogović TZ, "Inhalation plus intravenous colistin versus intravenous colistin alone for treatment of ventilator associated pneumonia" 9 (9): 29-33, 2014

16 Pogue JM, "Incidence of and risk factors for colistinassociated nephrotoxicity in a large academic health system" 53 : 879-884, 2011

17 Pogue JM, "Incidence of and risk factors for colistinassociated nephrotoxicity in a large academic health system" 53 : 879-884, 2011

18 O’Brien JM Jr, "Excess body weight is not independently associated with outcome in mechanically ventilated patients with acute lung injury" 140 : 338-345, 2004

19 Steinfort DP, "Effect of long-term nebulized colistin on lung function and quality of life in patients with chronic bronchial sepsis" 37 : 495-498, 2007

20 Pugin J, "Diagnosis of ventilator-associated pneumonia by bacteriologic analysis of bronchoscopic and nonbronchoscopic “blind” bronchoalveolar lavage fluid" 143 : 1121-1129, 1991

21 Falagas ME, "Colistin: the revival of polymyxins for the management of multidrug-resistant gram-negative bacterial infections" 40 : 1333-1341, 2005

22 Jensen T, "Colistin inhalation therapy in cystic fibrosis patients with chronic Pseudomonas aeruginosa lung infection" 19 : 831-838, 1987

23 Gurjar M, "Colistin for lung infection: an update" 3 : 3-, 2015

24 DeRyke CA, "Colistin dosing and nephrotoxicity in a large community teaching hospital" 54 : 4503-4505, 2010

25 Horan TC, "CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting" 36 : 309-332, 2008

26 Alothman GA, "Bronchial constriction and inhaled colistin in cystic fibrosis" 127 : 522-529, 2005

27 Katzmarzyk PT, "Body mass index and risk of cardiovascular disease, cancer and all-cause mortality" 103 : 147-151, 2012

28 Kofteridis DP, "Aerosolized plus intravenous colistin versus intravenous colistin alone for the treatment of ventilatorassociated pneumonia: a matched case-control study" 51 : 1238-1244, 2010

29 Bellomo R, "Acute renal failure - definition, outcome measures, animal models, fluid therapy and information technology needs: the Second International Consensus Conference of the Acute Dialysis Quality Initiative (ADQI) Group" 8 : R204-R212, 2004

30 Knaus W, "APACHE II: a severity of disease classification system" 13 : 818-829, 1985

31 Levey AS, "A New Equation to Estimate Glomerular Filtration Rate" 150 : 604-612, 2009